Inhibrx Biosciences, Inc. (INBX) Stock Profile — Insider Trades & Financials

Revenue$0

Net Income-$32.8M

EPS$-6.93

Market Cap$980.6M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Mark Lappe

CEO & Executive Director

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Founded: 2010
Employees: 161
Headquarters

⚡

Core Efficiency

ROE?

-410.78%

ROA?

-22.42%

D/E Ratio?

17.33

📊

Profitability Ratios

Current Ratio?

3.93

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 10, 2026 (in 123 days)

Annual Report (10-K) — Based on filing pattern

Aug 10, 2026

Predicted10-K

Mar 19, 2026

10-KQ4 20258d after period end

Nov 14, 2025

10-QQ3 20257d after period end

Aug 13, 2025

10-QQ2 20255d after period end

May 14, 2025

10-QQ1 20255d after period end

Mar 17, 2025

10-KQ4 202417d after period end

Nov 14, 2024

10-QQ3 20246d after period end

Aug 13, 2024

10-QQ2 20244d after period end

Loading company sections...

Inhibrx Biosciences, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness